Literature DB >> 29853532

123I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study.

Junji Komatsu1, Miharu Samuraki1, Kenichi Nakajima2, Heii Arai3, Hiroyuki Arai4, Tetsuaki Arai5, Takashi Asada5, Hiroshige Fujishiro6, Haruo Hanyu7, Osamu Iizuka8, Eizo Iseki6, Kenichi Kashihara9, Kenji Kosaka10, Hirotaka Maruno11, Katsuyoshi Mizukami12, Yoshikuni Mizuno13, Etsuro Mori8, Hiroyuki Nakamura14, Seigo Nakano15, Kenji Nakashima16, Yoshiyuki Nishio8, Satoshi Orimo17, Akira Takahashi18, Junichi Taki2, Takahiko Tokuda19, Katsuya Urakami20, Kumiko Utsumi21, Kenji Wada16, Yukihiko Washimi22, Shouhei Yamashina23, Junichi Yamasaki23, Mitsuhiro Yoshita1,24, Masahito Yamada1.   

Abstract

BACKGROUND AND
PURPOSE: We previously reported the usefulness of iodine-123 metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy for differentiation of dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) in a cross-sectional multicentre study. The aim of this study was, by using reassessed diagnosis after 3-year follow-up, to evaluate the diagnostic accuracy of 123I-MIBG scintigraphy in differentiation of probable DLB from probable AD.
METHODS: We undertook 3-year follow-up of 133 patients with probable or possible DLB or probable AD who had undergone 123I-MIBG myocardial scintigraphy at baseline. An independent consensus panel made final diagnosis at 3-year follow-up. Based on the final diagnosis, we re-evaluated the diagnostic accuracy of 123I-MIBG scintigraphy performed at baseline.
RESULTS: Sixty-five patients completed 3-year follow-up assessment. The final diagnoses were probable DLB (n=30), possible DLB (n=3) and probably AD (n=31), and depression (n=1). With a receiver operating characteristic curve analysis of heart-to-mediastinum (H/M) ratios for differentiating probable DLB from probable AD, the sensitivity/specificity were 0.77/0.94 for early images using 2.51 as the threshold of early H/M ratio, and 0.77/0.97 for delayed images using 2.20 as the threshold of delayed H/M ratio. Five of six patients who were diagnosed with possible DLB at baseline and with probable DLB at follow-up had low H/M ratio at baseline.
CONCLUSIONS: Our follow-up study confirmed high correlation between abnormal cardiac sympathetic activity evaluated with 123I-MIBG myocardial scintigraphy at baseline and the clinical diagnosis of probable DLB at 3-year follow-up. Its diagnostic usefulness in early stage of DLB was suggested. TRIAL REGISTRATION NUMBER: UMIN00003419. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29853532     DOI: 10.1136/jnnp-2017-317398

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.

Authors:  Melissa J Armstrong; David J Irwin; James B Leverenz; Noheli Gamez; Angela Taylor; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

2.  Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions.

Authors:  Masahito Yamada; Junji Komatsu; Keiko Nakamura; Kenji Sakai; Miharu Samuraki-Yokohama; Kenichi Nakajima; Mitsuhiro Yoshita
Journal:  J Mov Disord       Date:  2019-11-08

3.  Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity.

Authors:  Koichi Okuda; Kenichi Nakajima; Chiemi Kitamura; Yumiko Kirihara; Mitsumasa Hashimoto; Seigo Kinuya
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

4.  Neuroimaging alterations in dementia with Lewy bodies and neuroimaging differences between dementia with Lewy bodies and Alzheimer's disease: An activation likelihood estimation meta-analysis.

Authors:  Wen-Ying Ma; Min-Jie Tian; Qun Yao; Qian Li; Fan-Yu Tang; Chao-Yong Xiao; Jing-Ping Shi; Jiu Chen
Journal:  CNS Neurosci Ther       Date:  2021-12-06       Impact factor: 5.243

5.  Dynamic planar scintigraphy for the rapid kinetic measurement of myocardial 123I-MIBG turnover can identify Lewy body disease.

Authors:  Yoshitaka Kumakura; Yuji Shimizu; Masatsugu Hariu; Ken-Ichi Ichikawa; Norihito Yoshida; Masato Suzuki; Satoru Oji; Shinya Narukawa; Haruo Yoshimasu; Kyoichi Nomura
Journal:  EJNMMI Res       Date:  2021-12-14       Impact factor: 3.138

6.  A prospective multicenter validation study of a machine learning algorithm classifier on quantitative electroencephalogram for differentiating between dementia with Lewy bodies and Alzheimer's dementia.

Authors:  Yukiko Suzuki; Maki Suzuki; Kazue Shigenobu; Kazuhiro Shinosaki; Yasunori Aoki; Hirokazu Kikuchi; Toru Baba; Mamoru Hashimoto; Toshihiko Araki; Kristinn Johnsen; Manabu Ikeda; Etsuro Mori
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

7.  Autopsy Validation of the Diagnostic Accuracy of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy for Lewy Body Disease.

Authors:  Tomoyasu Matsubara; Masashi Kameyama; Noriko Tanaka; Renpei Sengoku; Makoto Orita; Ko Furuta; Atsushi Iwata; Tomio Arai; Hirofumi Maruyama; Yuko Saito; Shigeo Murayama
Journal:  Neurology       Date:  2022-03-07       Impact factor: 9.910

8.  Cardiac 123I-MIBG normal uptake values are population-specific: Results from a cohort of controls over 60 years of age.

Authors:  G Roberts; J J Lloyd; J P M Kane; R Durcan; S Lawley; K Howe; G S Petrides; J T O'Brien; A J Thomas
Journal:  J Nucl Cardiol       Date:  2019-09-16       Impact factor: 5.952

Review 9.  Neuroimaging in Dementia With Lewy Bodies.

Authors:  Abhishikta Saha; Dipanjan Banerjee
Journal:  Cureus       Date:  2021-06-16

Review 10.  Dementia with Lewy bodies: an update and outlook.

Authors:  Tiago Fleming Outeiro; David J Koss; Daniel Erskine; Lauren Walker; Marzena Kurzawa-Akanbi; David Burn; Paul Donaghy; Christopher Morris; John-Paul Taylor; Alan Thomas; Johannes Attems; Ian McKeith
Journal:  Mol Neurodegener       Date:  2019-01-21       Impact factor: 14.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.